found that JAK1 inhibitors improved T cell differentiation and function by blocking persistent type I interferon (IFN‐I) signals, and in a Phase II clinical study, the therapeutic effect of combined PD‐1 inhibitors for first‐line treatment of advanced NSCLC was two to three times that of existing first‐line immune treatments.64 The gene discussed is JAK1; the disease is non-small cell lung carcinoma.